Arrowhead Pharmaceuticals, INC 8-K filings

Arrowhead Pharmaceuticals announced robust fiscal 2026 third quarter results, highlighting significant progress in clinical development, commercialization of REDEMPLO, and strategic partnerships.

Arrowhead Pharmaceuticals, Inc. announced the appointment of Dr. Matt Cohen as a new director, effective June 12, 2026, bringing over 25 years of healthcare investment experience.

Arrowhead Pharmaceuticals announced its fiscal 2026 second quarter results, highlighting strong commercial execution for REDEMPLO and advancements in its R&D pipeline.

Arrowhead Pharmaceuticals announced robust fiscal first quarter 2026 results, driven by the U.S. launch of REDEMPLO and significant partnership milestones.

Arrowhead Pharmaceuticals, Inc. has issued $775 million in 0.00% Convertible Senior Notes due 2032, alongside capped call transactions to manage potential share dilution.

Arrowhead Pharmaceuticals priced concurrent public offerings of $625 million in convertible senior notes and 3.1 million shares of common stock, including pre-funded warrants, to raise approximately $897.9 million in net proceeds for general corporate purposes.

Arrowhead Pharmaceuticals announced positive interim Phase 1/2a clinical trial results for its RNAi-based obesity therapeutics, ARO-INHBE and ARO-ALK7, demonstrating significant weight and fat reduction.

Arrowhead Pharmaceuticals announced its 2025 fiscal year-end results, highlighted by the FDA approval of REDEMPLO, its first commercial-stage siRNA medicine for familial chylomicronemia syndrome (FCS).

Arrowhead Pharmaceuticals announced FDA approval for REDEMPLO (plozasiran), its first commercial-stage siRNA medicine, to treat familial chylomicronemia syndrome (FCS).

Ionis Pharmaceuticals has filed a patent infringement lawsuit against Arrowhead Pharmaceuticals over its investigational drug plozasiran for Familial Chylomicronemia Syndrome.

Arrowhead Pharmaceuticals has filed a lawsuit against Ionis Pharmaceuticals to protect its investigational drug plozasiran from patent infringement claims.

Arrowhead Pharmaceuticals entered an exclusive global licensing and collaboration agreement with Novartis for its preclinical Parkinson's disease therapeutic, ARO-SNCA, and its TRiMTM platform.

Arrowhead Pharmaceuticals announced its fiscal 2025 third-quarter results, highlighting significant progress in its clinical pipeline, strategic partnerships, and a strong balance sheet.

Arrowhead Pharmaceuticals announces positive fiscal Q2 2025 results, highlighted by a significant collaboration with Sarepta Therapeutics and progress towards the potential launch of plozasiran.

Arrowhead Pharmaceuticals announces the retirement of CFO Ken Myszkowski and the appointment of Daniel Apel as the new CFO, effective May 13, 2025.

Arrowhead Pharmaceuticals successfully held its 2025 Annual Meeting of Stockholders, where key proposals, including the election of directors and ratification of auditors, were approved.

Arrowhead Pharmaceuticals reported its fiscal 2025 first-quarter results, featuring the FDA's acceptance of the plozasiran NDA and a significant collaboration agreement with Sarepta Therapeutics.

Arrowhead Pharmaceuticals appoints Douglas Ingram, CEO of Sarepta Therapeutics, to its Board of Directors, effective February 6, 2025, as part of an Investor Rights Agreement with Sarepta.

Arrowhead Pharmaceuticals reports the retirement of board chairman Douglass Given, effective December 31, 2024, and the expected appointment of Douglas S. Ingram in early 2025.

Arrowhead Pharmaceuticals reported its fiscal year 2024 results, highlighting significant financial deals with Sarepta Therapeutics and Sixth Street, alongside progress in its drug pipeline, notably the submission of an NDA for plozasiran.

Arrowhead Pharmaceuticals announced strong fiscal third quarter results, highlighted by positive clinical trial data and a significant $500 million financing agreement.

Arrowhead Pharmaceuticals announced its fiscal 2024 second quarter results, showcasing progress in clinical trials, a $50 million milestone payment, and a $450 million capital raise.

Arrowhead Pharmaceuticals successfully held its 2024 Annual Meeting, electing seven directors, approving executive compensation, and ratifying KPMG as independent auditors.

Arrowhead Pharmaceuticals has amended the effective date of Hongbo Lu's appointment to the Board of Directors and increased the board size from seven to eight members, both effective March 15, 2024.

Arrowhead Pharmaceuticals has appointed Hongbo Lu, Ph.D., as an independent director, effective April 1, 2024, increasing the board size from seven to eight members.

Arrowhead Pharmaceuticals reported its fiscal 2024 first quarter results, highlighted by a strategic restructuring to focus on late-stage clinical development and a significant reduction in operating cash burn.

Arrowhead Pharmaceuticals' Chief Medical Officer, Javier San Martin, M.D., will depart on February 1, 2024, with Bruce Given, M.D., stepping in as Chief Medical Scientist to assist with the transition.